rss
Br J Ophthalmol 2009;93:316-321 doi:10.1136/bjo.2007.135111
  • Clinical science
    • Original Article

Conjunctival hyperaemia with the use of latanoprost versus other prostaglandin analogues in patients with ocular hypertension or glaucoma: a meta-analysis of randomised clinical trials

This article has been Unlocked
  1. F Honrubia1,
  2. J García-Sánchez2,
  3. V Polo1,
  4. J M Martínez de la Casa2,
  5. J Soto3
  1. 1
    Ophthalmology Service, Hospital Miguel Servet, Zaragoza, Spain
  2. 2
    Ophthalmology Service, Hospital Clínico, Madrid, Spain
  3. 3
    Medical Unit, Pfizer Spain, Madrid, Spain
  1. Dr J Soto, Medical Unit, Pfizer Spain, Avda de Europa 20-B, Parque Empresarial de la Moraleja, 28108 Alcobendas, Madrid, Spain; javier.soto.alvarez{at}pfizer.com
  • Accepted 15 October 2008
  • Published Online First 19 November 2008

Abstract

Aim: To conduct a meta-analysis of randomised clinical trials (RCTs) in order to evaluate the development of conjunctival hyperaemia after the use of latanoprost versus travoprost and bimatoprost, in patients with ocular hypertension or glaucoma.

Methods: In order to identify the potentially relevant RCTs, a systematic literature retrieval was conducted in Medline, Embase and Cochrane Controlled Trials Register (1995–April 2007) databases The outcome measure was the appearance of conjunctival hyperaemia during the study. Statistical analyses included the calculation of odds ratio (OR) and its respective confidence interval, along with intertrial statistical heterogeneity. Publication bias was evaluated through a funnel plot, and a sensitivity analysis was also performed.

Results: In total, 13 RCTs involving 2222 patients with ocular hypertension or glaucoma were included, five comparing latanoprost versus travoprost, seven comparing latanoprost versus bimatoprost and one comparing latanoprost versus travoprost and bimatoprost. The combined results showed that latanoprost produced lower occurrence of conjunctival hyperaemia than both travoprost (OR = 0.51; 95% CI 0.39 to 0.67, p<0.0001) and bimatoprost (OR = 0.32; 95% CI 0.24 to 0.42, p<0.0001). No significant heterogeneity was found between the included RCTs. There was no evidence of publication bias. In the sensitivity analysis performed, none of the clinical trials included in this meta-analysis has an important impact in the global estimation of OR.

Conclusions: According to available data, the use of latanoprost is associated with a lower incidence of conjunctival hyperaemia when compared with travoprost and bimatoprost in the treatment of patients with ocular hypertension or glaucoma.

Footnotes

  • Competing interests: JS is an employee of Pfizer Spain. FH, JG-S, VP and JMM have participated in advisory boards for several pharmaceutical companies (Pfizer, Alcon, Allergan and MSD).

  • This is an open-access article distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

This article has been Unlocked

This Article

  1. Free via Creative Commons: CC
  2. Abstract
  3. Full text
  4. PDF
  5. All versions of this article:
    1. bjo.2007.135111v1
    2. 93/3/316 most recent

Responses

  1. Submit a response
  2. No responses published

Register for free content

The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.